Jiangsu Sinopep-Allsino Biopharmaceutical (SHA:688076) received good manufacturing practice compliance certifications from South Korea and China's Jiangsu province.
These are semaglutide and fulvestrant active pharmaceutical ingredients (API) for export to South Korea as well as epalrestat and sodium picosulfate APIs for domestic production, according to a Tuesday filing with the Shanghai bourse.
Shares of the biopharmaceutical company were down 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.